Biota (Relenza) .... Bald Übernahme durch Glaxo ?? - 500 Beiträge pro Seite

[Massel]

Biota (WKN: 887853) ist ein kleiner niedlicher Biotechwert aus Australien, der 7% der Relenza-Einnahmen von Glaxo abbekommt.
Neulich verkündete Glaxo noch eine Verdreifachung der Relanzproduktion auf 190 Mio Dosen für 2009 an.

1.) Biota profitiert als schon jetzt mit echten Einnahmen von der Pandemiesituation, wobei die Zeichen für Relenza durch die zunehmende Tamiflu-Resistenz (Roche) immer besser stehen.

2.) Das niedrige KGV von Biota ist gerade zu eine Witz für ein Biotech-Unternehmen mit def. Einnahmen.

3.) Hinzu kommt noch die Phantasie der Pipline, mit der bereits positven Phase 2 von LANI, Phase 3 - Ergebnisse sollen bald kommen ! ,haben die schon den 2 Kanditadten, der in die Fussstapfen von Relenza treten könnte. (Patent läuft 2014 für Relenza aus).

Kurzfristig stehen die Jahreszahlen an (19.8) Fiscalyear bis einschließlich 30.6.2009. Aufgrund der Relenza-Einnahmen sollte diese positiv ausfallen.

Biota steht also nicht ohne Grund momentan auf einem Allzeithoch,
ist meiner Meinung aber noch krass unterbewertet. 4 AUD wären eher passend; aber locker....

Glaxo dürfte schon schwer am überlegen sein, ob Biota nicht eine interessanter Kauf ist. Vielleicht haben die auch schon begonnen sich einzudecken, denn in den vergangen Wochen kennt der Kurs nur eine Richtung. Selbst an schlechten Tagen wie gestern und vorgestern legt Biota leicht zu.....

Hauptvolumen läuft in Australien.

Die Diskusion sei hiermit eröffnet !

Gruß
massel

[VanGillen]

WKN 887853
ISIN AU000000BTA1
Symbol BZK
Bezeichnung BIOTA HOLDINGS LTD. Registered Shares o.N.





Jahreshoch / -tief 1,21 (06.08) 0,14 (02.01)
52 Wochenhoch / -tief 1,21 (06.08)

[Massel]

FETTE NEWS

Biota ready to commercialise flu drug
Monday August 10, 2009, 12:36 pm

Anti-flu drug developer Biota Holdings Ltd says the way is open to commercialise its latest anti-flu compound, laninamivir, following successful results from late-stage trials of the drug in Asia.

Biota said on Monday that laninamivir was effective in the treatment and prevention of seasonal flu, bird flu and swine flu.

The company said that the drug, taken via inhalation, differed from other flu drugs in that it required just one dose to treat flu and a once-weekly dose to prevent flu.

Biota managing director Peter Cook said the class of drugs to which laninamivir belonged - neuraminidase inhibitors - affected the mechanism whereby the virus, having replicated in the lung cell, releases itself from that cell.

"All influenza viruses use this same mechanism and these drugs all block that occurring, so effectively creating a `still birth' of the new virus," he said.

Biota announced on Monday that it had successful results from Phase III clinical trials in Asia of the compound CS-8958, which had been assigned the name, laninamivir, by the World Health Organisation.

"This is an historic development, one that has been many years in the making," Mr Cook told reporters.

"While there is much work ahead, it is reasonable to say that commercialisation of laninamivir is now within sight."

Mr Cook said laninamivir would help to meet the global need for a diversified basket of anti-viral drugs to fight influenza.

"The product offers a once-only dose for treatment of influenza and a once-weekly dose for prophylaxis," he said.

"These two attributes provide particular benefits for stockpiling through improved patient compliance, reduced storage space and lower freight costs.

"The success of these trials takes Biota another step closer to realising the valuable income stream from laninamivir."

Biota co-owns laninamivir with Japanese pharmaceutical group Daiichi Sankyo Co, which funded the Japanese trials.

Daiichi Sankyo has the rights to make and market laninamivir in Japan.

Biota said Daiichi Sankyo now was seeking approval from the Japanese regulatory authority to market laninamivir in Japan, with submission anticipated by March 2010.

Biota will receive royalties on sales of laninamivir and fixed-sum payments upon achievement of certain sales milestones.

Mr Cook said Biota now was seeking a commercial licensing partner for territories outside Japan and would work on clinical studies needed to support the registration of laninamivir in the United States and Europe.

Under the commercialisation and licence agreement between Biota and Daiichi Sankyo, the parties will share commercial returns from licensing outside Japan.

Mr Cook said the US regulatory authority would require a replication of the Asian Phase III tests in a western market.

But, he said, in the event of a "turn for the worst" in the incidence of swine flu, the US Food and Drug Administration may accept the studies done elsewhere in the world for approval under emergency circumstances.

Biota also said on Monday that development of its respiratory syncytial virus (RSV) anti-viral drug BTA9881 had been halted.

RSV is the most common respiratory infection for infants and children.

Biota said a Phase Ia clinical trial for BTA9881 had been completed, but the BTA9881 drug profile did not meet the safety margin required for continued development.

Consequently, Biota would terminate a license and collaboration agreement with AstraZeneca UK.

All rights in the Biota RSV program would revert to Biota.

Biota said it would invest about $3 million in the 2010 full year in the development of promising back-up compounds and to re-licence the program in the future.

Biota shares were 11 cents higher at $2.17 at 1201 AEST on Monday.
-----------------------------------------------

Her mit dem FDA Approval und wir gehen durch die DECKE !!!

gruß
massel

[Massel]

Ich weiss zwar nicht was Glaxo oder Roche ggf. in der Pipline haben, aber das man LANINAMIVIR nur einmal wöchentlich (anstelle von 10 Tamiflu Tabletten) nehmen muss, dass muß man sich mal auf der Zunge zergehen lassen...
Sollte mich nicht wundern wenn wir bald einen takeover bid seitens Roche oder Glaxo wegen LANINAMIVIR bei Bioata sehen, denn LANINAMIVIR hatte ohne weiteres das Zeug dazu Tamiflu den Rang 1 bei den Grippemedikamenten abzulaufen, wenn ich die Zeichen richtig deute....

Eine andere Frage die ich mir nun stelle:

Sind Grippeimpfungen/mittel nun überhaupt noch notwendig ?

gruß
massel

[Massel]

Mal ein Bißchen was für die Fantasie:


Bayer May Be Ready for Deals After Lost Intervet Bid (Update1)
Share | Email | Print | A A A

By Eva von Schaper and Aaron Kirchfeld

Aug. 11 (Bloomberg) -- Bayer AG’s unsuccessful bid for Schering-Plough Corp.’s animal-health business last month shows Chief Executive Officer Werner Wenning is prepared to make large acquisitions again.

Wenning, 62, who in March said takeovers were not a priority, offered 6 billion euros ($8.5 billion) to 7 billion euros for Schering-Plough’s Intervet unit and considered a 3 billion-euro share sale to help fund the purchase, according to two people familiar with the situation. Bayer lost the deal after the sale was scrapped by the owner.

Buying Intervet would have been Bayer’s second-biggest acquisition after its 17 billion-euro takeover of Schering AG in 2006, data compiled by Bloomberg show. Wenning is making health care the mainstay of the German chemicals and pharmaceutical company and plans to whittle down debt toward 10 billion euros this year, giving Bayer more flexibility for deals.

“They’ve shown they can handle the heavy lifting of a big acquisition,” said Karl-Heinz Scheunemann, an analyst at Landesbank Baden-Wuerttemberg in Stuttgart, Germany.

Bayer fell as much as 2.2 percent in Frankfurt trading, adding to yesterday’s 1.5 percent decline. The shares fell 63 cents, or 1.4 percent, to 43.67 euros as of 10:56 a.m.

The CEO may now turn his attention to drug targets in the U.S. and Asia, said one of the people, who declined to be identified because the information isn’t public. Bayer spokesman Christian Hartel declined to comment on the Intervet bid.
When Opportunity Knocks

Bayer had obtained loan commitments from at least three banks and also considered a convertible bond or hybrid securities to raise funding, the people said. The non-binding offer shows the German company is willing to make multi-billion- euro acquisitions if opportunities arise though it may typically seek smaller, more targeted deals, one of the people said.

Bayer lost out when Merck & Co., which is buying Schering- Plough, opted to keep Intervet and sell its share of the Merial veterinary unit to partner Sanofi-Aventis SA instead. Whitehouse Station, New Jersey-based Merck has to sell animal-health assets to appease competition regulators.

Wenning, a Bayer veteran who started as a commercial trainee in 1966, has branched out in health care to reduce the dependence on chemicals since taking the helm in 2002.

During his tenure, Bayer shares have returned an average 6.9 percent annually including dividends through last week, compared with a 6.7 percent annual increase for the Bloomberg Europe Chemicals Index. The stock is up more than 6 percent this year.

Foiling Merck KGaA

Wenning purchased Roche Holding AG’s over-the-counter medicines business for 3.6 billion Swiss francs ($3.3 billion) in 2005, the same year in which he spun off Bayer’s rubber chemicals unit to shareholders. His biggest undertaking was the acquisition of Schering, foiling a hostile takeover attempt of the Berlin-based company by Merck KGaA.

Arthur Higgins, who heads the company’s health-care unit, said in March that Bayer was interested in buying rights to potential new medicines and would consider acquiring a company or a unit to expand in consumer health.

Bayer wants at least 30 percent of health-care sales to come from non-drug fields, company executives said at a meeting with analysts in June, according to slides posted on the company’s Web site.

Bayer now gets about 50 percent of its revenue from the health-care unit. Sales from the Betaseron multiple sclerosis treatment, gained through Schering, and newer pharmaceuticals are helping the company to weather a decline in plastics. Bayer is also one of the biggest makers of crop treatments.

Debt Reduction

Bayer’s 2009 debt-reduction target would bring its net debt to earnings before interest, depreciation, taxes and amortization ratio to below 2, lower than the 2.5 level deemed to qualify for an investment grade credit rating, according to Jochen Schlachter, a senior credit analyst at UniCredit SpA in Munich.

The debt-to-Ebitda ratio is one of the measurements used by rating agencies to help determine a company’s creditworthiness.

Bayer’s credit rating was reduced by Standard & Poor’s Ratings Services after the Schering acquisition was announced. Its long- and short-term corporate credit rating now stands at “A-/A-2.”

“A capital increase would be seen very positively by the agencies,” Schlachter said.

To contact the reporters on this story: Eva von Schaper in Munich at [e-mail]; To contact the reporter on this story: Aaron Kirchfeld in Frankfurt at [e-mail]

Last Updated: August 11, 2009 05:07 EDT
-------------------------------------------------------

Na, " Biota " das wär doch mal was Neues für Bayer, in den Grippemarkt einzusteigen und sich direkt Anteil von den Relenza-Einnahmen Glaxos greifen....

gruß
massel

[Massel]

Das ist so ne geile Aktie / Unternehmen !!

AUSTRALIA'S BIOTA HOLDINGS TO RETURN CASH TO SHAREHOLDERS
Wednesday 08/12/2009 11:46 PM ET - Asia Pulse

Australia's Biota Holdings Ltd (ASX:BTA) plans to return $A20 million (US$16.58 million) in cash to shareholders, following a review of its cash needs.

The Melbourne-based influenza drug developer said on Thursday the return will equate to about 11 cents per share.

Biota stock closed on Wednesday at $2.04 a piece.

"The return follows a recent and extensive review of the cash requirements for the growth of the business and the improved trading conditions forecast in the near term for the company," it said in a statement.

The record date for the payment will be November 19, subject to the receipt of shareholder approval if needed at Biota's annual general meeting on November 12.

"Shareholders would receive payment in early December 2009," it said.

Biota and its advisor, Deloitte, have sought a class ruling for shareholders from the Australian Taxation Office (ATO) in relation to whether the taxation treatment associated with the payment may be treated as a return of capital.

"To the extent that the ATO contends that any part of the payment is not a capital return, and considered an unfranked dividend, Biota will be obligated to withhold tax from those shareholders where relevant tax details are not recorded," it said.

Biota will release its annual results on August 19.
---------------------------------

gruß
massel

[Massel]

von: www.finanznachrichten.de > biota

http://www.news.com.au/heraldsun/story/0%2C21985%2C25925983-…


Olga Galacho

August 14, 2009 12:00am

INFLUENZA drug developer Biota has remained true to its word and will return $20 million to long-suffering shareholders.

In a move that strongly signals the company is expecting to collect generous royalties from Relenza, Biota's registry may also soon see interest from institutional investors, which have until now been shy about the stock.

Uncertainty still surrounds the tax treatment of the cash payment, which equates to a return of 11 a share, as the company awaits a ruling from the Australian Taxation Office on whether the distribution is considered a return of capital.

Biota said yesterday the payout followed a review of the cash requirements for the business' growth and shareholders would get to vote on it at the annual meeting in November.

Chief executive Peter Cook told BusinessDaily it was fair to assume from yesterday's announcement that Biota was expecting to collect more than enough income to complete its program of clinical trials for new products and still have enough to hand some back to shareholders.

"The company has said all along that it is keeping its capital management under close scrutiny and with completion of that review, we have decided to return some of it," Dr Cook said.

The inventor of Relenza, the anti-viral drug licensed to GlaxoSmithKline, will post its full-year results on Wednesday, he said.

"Our understanding of GlaxoSmithKline's order book is that there will be enough left in our kitty."

Biota last raised capital from shareholders in 2005 as it prepared to take GSK to court over allegations the pharmaceutical giant had not marketed Relenza strongly enough.

The drawn-out legal proceedings culminated in an out-of-court settlement last year for a fraction of the costs, Biota had claimed.

One biotech sector analyst said yesterday's decision was further evidence that Biota was coming of age and expecting to earn "vast sums of money".

"At the start of the week, Biota didn't even skip a beat when it announced AstraZeneca had handed back a large program," said the analyst, in reference to the termination of trials and a licence deal for its respiratory syncytial virus therapy.

However, the same day the biotech delivered some good news, too, with successful results posted for late-stage trials of its second generation flu treatment, laninamivir, in Japan.

Shareholders on the books by November 19 will be eligible for the cash payment in early December.

Biota shares firmed 2 per cent or 4 to $2.08 yesterday.

----------------------------

gruß
massel

[Massel]

als ich bin mit dem Wochenausklang , sagen wir mal: "einverstanden"....

KEINE Gewinnmitnahmen zum Wochenende lassen für nächste Woche erahnen wo es hingeht.

Ich habe noch einen wirklich passenden Kommentar zu der letzten Meldung /News bezogen auf die Rückzahlung der 20 Mio (11 cents je Share) an die Aktionäre gefunden:

Also yesterday, established flu-buster Biota (BTA), $2.08, announced a $20m, 11c-a-share capital return. Given it's easier to retrieve a baby from a rottweiler's gaping jaws than cash from a biotech, calling the news a bolt from the blue is an understatement.

Ich denke treffender kann man es kaum formulieren, die meisten haben anscheinend nicht verstanden welch "fullminantes" Ereignis da eigentlich stattgefunden hat. Im Übrigen dürfte, nein SOLLTE diese Nachricht einigen Großkonzernen die Charmesröte ins Gesicht treiben;

Da schickt sich eine kleine Biotech-Firma mit rund 200 Mio Marktkap. an seine Aktionären rund 5% Bonus auszuschütten.

Ich bin stolz in diese Firma und dessen Mangement investiert zu haben. Unsere Herrn Manager hätten sich erst einmal selber die Taschen per Gehaltserhöhung voll gemacht bevor die Aktionäre Geld bekommen hätten !!

Gruß und schönes Wochenende
massel

[Massel]

hier noch ein Artikel über die letzte News mit interessanten letzen Abschnitt:

Biota to return $20 million to shareholders

Melbourne, Australia — 13 August 2009 -- Biota Holdings Limited (ASX: BTA) today announced that it intends to make a return of $20 million to shareholders. The return follows a recent and extensive review of the cash requirements for the growth of the business and the improved trading conditions forecast in the near term for the company.

The record date for the payment will be 19 November 2009, subject to receiving shareholder approval if needed, at the forthcoming Annual General Meeting on 12 November 2009.

Shareholders would receive payment in early December 2009.

Biota and its advisor, Deloitte, have sought a Class Ruling for shareholders from the Australian Taxation Office (ATO) in relation to whether the taxation treatment associated with this payment, in whole or in part, may be treated as a return of capital. To the extent that the ATO contends that any part of the payment is not a capital return, and considered an unfranked dividend, Biota will be obligated to withhold tax from those shareholders where relevant tax details are not recorded. Biota will make a subsequent ASX announcement when the Class Ruling is available and confirm the relevant taxation implications.

Based on the current number of shares on issue, the cash payment is estimated to equate to approximately 11 cents per share.

Biota’s full year results, including a summary of its plans for growth, will be announced on 19 August 2009 and in subsequent presentations.

About Biota Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as RelenzaTM.

Biota research breakthroughs have included novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.

*Further information available at www.biota.com.au Investor / Analyst Enquiries Media Enquiries Biota Holdings Limited Jo Lynch Peter Cook Hinton & Associates T: [phone] T: [phone] Damian Lismore M: [phone] T: [phone]

----------------------------------------------------------

Wie man sieht, darf man Biota nicht nur auf die Schweinegrippe reduzieren... Die Pipline enthält u.a. einen weiteren Hoffnungsträger für ein echtes "Geisel" der Menscheit ; HEPATITS C !!

Jeder größere Pharmakonzern , der Biota nicht auf der Einkaufsliste stehen hat, kann eigentlich nicht richtig ticken oder sollte mal über sein Management nachdenken.....
Biota hat schließlich schon erfolgreich bewiesen nicht an Hirngespinsten zu arbeiten, sondern eine höchst erfolgreiches
Medikament entwickeln zu können (Relenza).


Gruß
massel

[Massel]

Ich denke Glaxo würde "Gift und Galle spucken" wenn die 7% Ihrer
Relenza-Einnahmen an Roche oder einen anderen Pharmakonzern abdrücken müssten....

Mit Daiichi Sankyo haben wir schon den 3ten Pharmakonzern der im Grippemittelmarkt um Biota mitmischt; immerhin Japans Nr.3

Fassen wir mal zusammen:

Roche muß ggf. Angst haben, dass Lanininamivir ggf. Tamiflu als Nr.1 im Markt ablöst und könnte sich 7% der noch austehenden und zukünftigen Relenza-Einnahmen greifen.
Alleine die Beiden Gründen reichen m.M. nach aus um eine Übernahme ins Auge zu fassen, zumal die Markkap. von Biota nur rund 200 mio beträgt. (+Pipline +Finanzsituation)

Glaxo muß Angst haben mit Relenza in der Bedeutungslosigkeit zu verschwinden wenn Tamiflu UND Laninamvir am Markt sind. Desweiteren
haben die sicherlich kein Interesse Roche oder einem anderen Pharmakonzern 7% Ihre Relanza Einnahmen zu geben. Man bedenke hier, dass der Löwenanteil der Relanzaeinnahmen noch nicht bezahlt wurde.. Verkäufe aus 2009 kommen ja erst noch in Bezahlung, oder ?

Daiichi Sankyo könnte sich durch eine Übernahme Biotas 100% der zukünftigen Laninamivir-Einnahmen sichern + 7% der jetzigen Relanza-Einnahmen. Müsste auch Angst haben ggf. einen neuen unberechenbaren Geschäftspartner zu bekommen, wenn sie nicht mitbieten.. Wahrlich keine schlechten Gründe, bin mir aber nicht sicher ob die genügend Munition haben wenn es um einen Übernahmekampf kommen sollte....(reicht aber schon, wenn die nur das Spielfeld betreten und den Preis treiben)

Fazit:

Gerade weil der Löwenanteil der Relanzeinnahmen noch kommt,
(das dürft eine sehr ordentlich Summe sein, die da noch aussteht)
die Lizenzen für Laninamvir bald vergeben werden wird es wahrscheinlich mit der Entscheidung um Biota sehr schnell
gehen wenn man richtig liegt....

Der potentielle Interessent für eine Übernahme kann somit eigentlich nicht lange warten wollen, denn schließlich müßte er auch Angst haben das Biota den Großteil seiner ZUKÜNFTIGEN Relenza-Einnahmen an die Aktionäre ausschüttet....

gruß
massel

[Massel]

Biota vermeldete am Mittwoch einen Nettoprofit von 38.2 mio AUD !

Im falle einer Übernahme darf
der zukünftige Eigentümer sich wohl über eine prall gefüllte Kasse freuen, denn die Relenzaprovisonen haben noch lange nicht ihren Zentit erreicht..(Glaxo will die Produktion noch dieses Jahr verdreifachen !)

Rechnet man diese Provisionseinnahmen für das FY 2009/2010 in den Kurs (schließlich wird ja an der Börse die Zukunft gehandelt); so bekommen wir ein KGV von cirka 2-4 !

Sowas nenne ich kras unterbewertet !

gruß
massel


Biota (WKN 887853)Ende 2009:Cash-Sonderzahlung von 0,11 AUD je Share http://www.biota.com.au/uploa/154/1021551_26lettertosharehol…

[Massel]

Es kommt Bewegung in den "Pillenmarkt".....

Swiss drugmaker Lonza bids US$458.5M for Patheon, outbids hostile JLL offer
Friday, 21 August 2009


TORONTO - Initial investor optimism over a potential friendly takeover bid for Canadian drugmaker Patheon Inc. (TSX:PTI) was tempered Friday after Patheon's biggest shareholder said it won't support the US$458.5-million offer.


Patheon shares soared Friday, but those gains were moderated when investment firm JLL Partners Inc., which has been attempting a hostile takeover of Patheon since last December, said it isn't interested in selling its majority stake in the company.


Patheon shares closed up 80 cents or 31 per cent at $3.38.


The new bid, from Swiss-based global contract manufacturer Lonza Group AG, is worth US$3.55 per share. Patheon said it trumps JLL Partners' offer of $2 per share.


But JLL issued a statement Friday indicating it would fight the Lonza bid.


"JLL will not enter into negotiations regarding the Lonza proposal and Patheon shareholders should be aware that a transaction with Lonza cannot occur without JLL's support," the New York-based company said.


JLL said it will not extend its own offer past the Aug. 26 deadline.


The Lonza proposal is conditional upon at least 67 per cent of Patheon's outstanding shares being tendered to the bid. Since JLL owns 57 per cent of Patheon, Lonza's bid cannot be approved without JLL's backing.


"The completion of the Lonza offer will depend, in our view, on JLL's overall receptivity to it and whether JLL is willing to surrender its own shares at US$3.55 per share," said Desjardins Securities analyst Maher Yaghi.


Yaghi said the Lonza offer is in line with Desjardins' C$3.75 target price valuation for Patheon.


Patheon's board of directors has put its support behind the Lonza bid after rejecting JLL's offer as inadequate.


The drugmaker went to court in May in an effort to remove board candidates nominated by JLL and stop the firm from voting its restricted voting shares acquired under the bid.


JLL has extended its offer for Patheon numerous times since its first bid, and has acquired 57 per cent of Patheon's stock during its campaign to acquire the company.

Paul Currie, chairman of Patheon's special committee of independent directors, said the Lonza deal offers a significant improvement over the JLL bid.

"Based on all of the information available to it, the special committee's view has been that Patheon continuing as an independent company is a more attractive alternative than the JLL offer," Currie said.

"The special committee also believes that the Lonza proposal would provide an excellent opportunity to secure the successful future development of Patheon, and that it is in the best interest of all Patheon shareholders to explore the Lonza proposal further."

The transaction is subject to Lonza satisfactorily completing its due diligence investigations and the approval of each company's board of directors.

Lonza is a supplier to the pharmaceutical, health-care and life science industries.

Patheon is one of the world's largest global contract drug manufacturers, doing business with multinational firms.

Switzerland is home to some of the world's biggest multinational drug companies, including Novartis AG and Roche, which have operations around the world.

Novartis is working to develop a vaccine against the so-called swine flu virus, or A(H1N1).

Roche makes Tamiflu, one of two medications recommended by the World Health Organization to treat infections of A(H1N1). The other is Relenza, made by the British drugs firm GlaxoSmithKline.

Patheon employs approximately 4,700 people at 10 manufacturing facilities in Canada, the U.S. and Europe.

[Massel]

Geil, gerade Nachricht in ital. erschienen:

Una ricerca dell' Imperial College di Londra offre nuove prospettive contro l'influenza A

Influenza suina: il Laninavir sfida il Tamiflu
Il nuovo farmaco sembra meglio del vecchio. I virologi: "E' una piccola rivoluzione"

© Matteo Clerici/NEWSFOOD.com - 22/08/2009


» LEGGI ANCHE
• Influenza suina, il virus resiste al Tamiflu. L' Oms: "Nessun cambiamento nelle terapie"
• Influenza suina, nel futuro 2 miliardi di malati
• Influenza suina: donne incinte, il pericolo si fa in quattro
Fino ad ora il Tamiflu (nonostante tutti i suoi difetti) era considerato il miglior farmaco nei trattamenti contro l'influenza suina: ora, le cose potrebbero cambiare.

Nuovi test clinici, condotti dall'Imperial College di Londra e descritti dalla rivista "Nature", mostrano come nella lotta contro il virus H1N1 possa essere usata una nuova sostanza, il Laninavir.

Il Laninavir, come il Tamiflu nasce come prodotto anti influenza, ma possiede numerosi vantaggi "originali".
Innanzitutto, i pazienti curati con esso hanno recuperato la salute come quelli curati con il Tamiflu e meno effetti collaterali, il vero grande handicap del vecchio farmaco. Inoltre, è sufficiente una singola medicazione (effettuata con un inalatore) e ciò rende il composto più facile da immagazzinare. In più, il Laninavir è impiegabile con profitto anche contro l'influenza aviaria (ed il virus H5N1).

Il dottor John Oxford, virologo specialista del Queen Mary, Università di Londra, descrive i risultati ottenuti come una "piccola rivoluzione" negli obiettivi a lungo termine delle terapie per l'influenza, arrivati proprio al momento giusto. Ma Oxford sottolinea come dovremmo aspettarci un lungo periodo di pandemia, in quanto la lotta contro di essa "sarà un tiro alla fune", lungo e non certo facile.

Il Laninavir è prodotto dalla Biota, compagnia australiana, che aspetta l'autorizzazione per vendere il prodotto sul mercato del Giappone (dove il virus H1N1 sta vivendo una fase di espansione). Biota sta inoltre cercando un partner commerciale per insediarsi anche in Europa e negli Stati Uniti; al momento, Roche, la compagnia farmaceutica svizzera, sembra il candidato più probabile.

Matteo Clerici

----------------------------------------

Babelfish übersetzt so:

A search dell' Imperial College of London offers perspective new against l' infuence To Infuence suina: the Laninavir challenge the Tamiflu The new drug seems better of the old one. The virologi: " E' a small rivoluzione" © Matteo Clerici/NEWSFOOD.com - 22/08/2009 ” LAWS ALSO • Infuence suina, the virus resists to the Tamiflu. L' The WHO: " No change in the terapie" • Infuence suina, in the future 2 billions of sick • Infuence suina: pregnant women, the danger is made in four Till now the Tamiflu (although all its defects) were considered the better drug in the treatments against l' infuence suina: now, the things could change. New tests clinicians, lead dall' Imperial College of London and described from the review " Nature" , they show as in the fight against virus H1N1 it can be used a new substance, the Laninavir. The Laninavir, as the Tamiflu is born like product infuence anti, but possesses numerous advantages " originali". In the first place, the patients cured with it have recovered the health like those cured with the Tamiflu and less effects collaterals, true the great handicap of the old drug. Moreover, a single medication (carried out with a inalatore is sufficient) and this renders the compound easier to store. In more, the Laninavir is employable with profit also against l' avian infuence (and virus H5N1). Dottor the John Oxford, specialist virologo of Queen Mary, University of London, describes the result obtained like a " small rivoluzione" in the objectives in the long term of the therapies for l' infuence, arrived own at the just moment. But Oxford emphasizes as we would have to wait for to us along period of pandemic, as the fight against of it " it will be a shooting to the fune" , along and not certainly easy. The Laninavir is produced from the Biota, Australian company, that it waits for l' authorization in order to sell the product on the market of Japan (where virus H1N1 is living a phase of expansion). Biota is moreover trying a partner trades them for insediarsi also in Europe and the United States; at the moment, Hoarse, the Swiss druggist company, seems the more probable candidate. Matteo Clerici

-------------------------------------------------------

Ja , ja ROCHE und auch GLAXO stehen richtig unter "Zugzwang wegen Laninamivir "

gruß
massel

[Massel]

Hab mir mal gerade den Rhytmus von HTM WILSON angeschaut;
die haben jeden Monat ein Staemant zu Biota gebracht;, meistens zum Ende des Monats.

Also dürfte WILSON sich diese Woche, spätestens am Montag nächster Woche zu Biota äußern.. Bin mal gespannt ob die ein bißchen mutiger, ach was heist mutiger, REALISTISCHER zu Biota äußern....


gruß
massel

[Massel]

Heiligs BLechle , wat iss den NU in Frankfurt LOS !!

11:59:59 bB 1,27 9000
11:57:57 1,26 2000
11:43:38 1,25 409
11:43:24 C 1,23 1
11:39:49 1,25 3000
11:38:18 1,23 280
11:38:10 bB 1,24 2000
11:34:25 1,23 1000
11:33:16 1,22 4100
11:33:03 bB 1,23 700



Stuttgart zieht auch an !!
12:01:33 1,27 1000
12:00:31 1,27 200
11:55:39 1,27 1500
11:45:33 1,27 820
11:45:23 1,25 2500
11:44:34 1,24 10000
11:36:09 1,23 5000
11:33:05 1,22 2000
11:31:56 1,22 6100
11:30:47 1,21 3000

[Massel]

aktuell

1,30

Zeit

26.08.09 12:21:42

Diff. Vortag

+9,24%

Tages-Vol.

82.646,75

Geh. Stück

65.470

Geld

1,28

Brief

1,32

Zeit

26.08. 12:22

Geld Stk.

7.700

Brief Stk.

10.000

[Massel]

Australien zieht nach !

Börse
Australien

Aktuell
2,11 AUD

Zeit
27.08.09 03:56

Diff. Vortag
+3,94 %

Tages-Vol.
753.549,42

Gehandelte Stück
358.613

-----------------------------------

gruß
massel

[Massel]

Schlusskurs Australien 2.16 AUD

-------------------------------------

Seit 10.45 tut sich auch wieder etwas bei uns...
kein Vergleich zu gestern, aber
immerhin an allen 4 deutschen Handelsplätzen...

Biota wird auf jeden Fall lebendiger...

gruß
massel

[Massel]

28.08.2009 23:27
Schweinegrippe fordert bereits mehr als 2.100 Tote
Seit dem Ausbruch im April dieses Jahres hat die Schweinegrippe mindestens 2.185 Menschen das Leben gekostet. Das geht aus einem Bericht der Weltgesundheitsorganisation (WHO) hervor, der heute vorgestellt wurde. Mit 557 bestätigten Todesfällen aufgrund einer Infektion mit dem Virus habe Brasilien die höchste Zahl an Opfern zu verzeichnen. Auf dem gesamten amerikanischen Kontinent seien 1.876 Menschen an der Krankheit gestorben. Mit 85 Toten liege Europa hinter der Asien-Pazifik-Region, in der es zu 203 Toten gekommen sei. In Afrika seien elf und im Nahen Osten zehn Menschen an dem Virus gestorben. Die WHO meldete des Weiteren mehr als 209.000 bestätigte Infektionen. Die reale Zahl sei allerdings höher, da eine Neuinfektion mittlerweile nicht mehr von den betroffenen Ländern gemeldet werden müsse. Die Schweinegrippe war bereits im Juni von der WHO zur Pandemie, also zur weltweiten Epidemie erklärt worden, was jedoch keinerlei Aufschluss über die Schwere der Infektion gibt. So sei die Lungenkrankheit Tuberkulose beispielsweise weitaus gefährlicher.

© 2009 dts Nachrichtenagentur

[Massel]

Vorerst letzter Beitrag in diesem Thread, da keine Resonanz:

Selbst bei einer morgigen Meldung "Schweinegrippe vorbei" würde das meiner Meinung nach Biota nicht sonderlich tangieren, denn mit
Laninamivir haben die anscheinend ein Allroundmittel in der Pipeline.

Der Run auf die Aktie um sich die 0.11 Cents je Share Cash zu sichern muß auch noch kommen, wer lässt bitte diese (momentan) 5% Rendite liegen ? Selbst bei einer Verdopplung des Kurses bis zum Stichtag im November wären es immerhin noch kurzfristige 2,5 % !!

Der Großteil der Relenzaeinnahmen kommt auch noch und ist schon in "trocken Tüchern", denn auch ohne Schweinegrippe fließen die georderten Mengen in die Stockpiles der jew. Regierungen. Glaxo würde nie eine Verdreifachung der Relenzaproduktion ankündigen, wenn die die Regierungs-Aufträge nicht schon in trockenen Tüchern hätten-

Zu guter letzt die Übernahmephantasie: Cash ist massig vorhanden, Medikamenten-Pipeline gut gefüllt , 99% der kleineren erfolgreichen Biotechs werden von größeren geschluckt.

Kann sein das ich gff. momentan etwas BLIND BIN UND etwas übersehen habe, aber ich finde absolut keinen Grund warum etwas mit Biota schief laufen sollte.

Sieht jemand einen Grund, was negatives ??
Bitte melden und schreiben, bin jederzeit bereit auch die negativen Punkt zu erörtern !

gruß
massel

[Massel]

Nächste Woche könnte es zur Sache gehen !


UN warns over swine flu in birds
By Sudeep Chand
Science reporter, BBC News



Turkeys have caught swine flu in Chile
The discovery of swine flu in birds in Chile raises concerns about the spread of the virus, the UN warns.

Last week the H1N1 virus was found in turkeys on farms in Chile. The UN now says poultry farms elsewhere in the world could also become infected.

Scientists are worried that the virus could theoretically mix with more dangerous strains. It has previously spread from humans to pigs.

However, swine flu remains no more severe than seasonal flu.

Safe to eat

Chilean authorities first reported the incident last week. Two poultry farms are affected near the seaport of Valparaiso.

Juan Lubroth, interim chief veterinary officer of the UN Food and Agriculture Organization (FAO), said: "Once the sick birds have recovered, safe production and processing can continue. They do not pose a threat to the food chain."

Chilean authorities have established a temporary quarantine and have decided to allow the infected birds to recover rather than culling them.

It is thought the incident represents a "spill-over" from infected farm workers to turkeys.

Canada, Argentina and Australia have previously reported spread of the H1N1 swine flu virus from farm workers to pigs.

Dangerous strains

The emergence of a more dangerous strain of flu remains a theoretical risk. Different strains of virus can mix together in a process called genetic reassortment or recombination.

So far there have been no cases of H5N1 bird flu in flocks in Chile.

However, Dr Lubroth said: "In Southeast Asia there is a lot of the (H5N1) virus circulating in poultry.

"The introduction of H1N1 in these populations would be of greater concern."

Colin Butter from the UK's Institute of Animal Health agrees.

"We hope it is a rare event and we must monitor closely what happens next," he told BBC News.

"However, it is not just about the H5N1 strain. Any further spread of the H1N1 virus between birds, or from birds to humans would not be good.

"It might make the virus harder to control, because it would be more likely to change."

William Karesh, vice president of the Wildlife Conservation Society, who studies the spread of animal diseases, says he is not surprised by what has happened.

"The location is surprising, but it could be that Chile has a better surveillance system.

"However, the only constant is that the situation keeps changing."
-----------------------------------------------------------------

Ich empfehle diesen Flu-Index: http://www.tickerspy.com/ts_index.php?id=248

um die Flu-Stocks im Auge zu halten.

Gruß
massel

[Massel]

NEWS: 3 Personen angeblich mit H1N1 UND H5N1 Virus infiziert !

Wenn das wirklich zutreffen sollte , wirds jetzt gefährlich !


Co-transmission of H5N1 with Pandemic H1N1 in Egypt? Recombinomics Commentary 18:16
September 2, 2009


A 35 year-old Italian tourist is one of three people believed to have been infected with A(H1N1) virus, or swine flu, as well as the H5N1 virus, known as avian flu. The patients are recovering in the Egyptian Red Sea resort of Hurghada, said Mohammed Rifai, director general of preventive medicine.

Rifai also spoke of a 28-year-old man who tested positive for both viruses, after arriving at the port of Safaga after a pilgrimage to Saudi Arabia.

"We are waiting the results of the tests that have already been carried out in some patients suspected of having been infected by the H5N1 and the A(H1N1)," said World Health Organisation spokesman Gregory Hartl in an interview with Adnkronos Salute.

The above comments raise concerns of co-infections of pandemic H1N1 and H5N1, as well as human to human co-transmission. This development would create serious pandemic concerns.

The ability of the pandemic H1N1 to infected multiple species has been demonstrated by the widespread outbreaks in swine. Outbreaks in Canada have been reported in three provinces (Alberta, Quebec, and Manitoba) as well as two locations in Argentina near Buenos Aires, as well as three locations in Australia, These swine infections demonstrate the ease of transmission from humans to swine, as well as swine to swine. Recent results in Chile also demonstrated transmission to turkeys, raising concerns that H1N1 could be silently transmitting to multiple mammalian and avian species.

The jump to avian raised concerns that the H1N1 could interact with H5N1, which is predominantly found in birds, including long range migratory birds. Recent data also demonstrated H5N1 in pikas at Qinghai Lake, which is a mammalian reservoir.

Results from Egypt also raised concerns of co-infections because of the large number of mild H5N1 cases and the concentration in children. The heavy concentration in children raised concerns of silent spread of H5N1 in adults, providing opportunities for co-infection, which could lead to the H1N1 "rescuing" H5N1 leading to co-transmissions.

The presence of both viruses in multiple individuals identified over a brief time period suggests the viruses are efficiently co-transmitting, which creates serious concerns due to co-infections, or exchanges of genetic information via reassortment or recombination. Mammalian polymorphisms have been noted in prior H5N1 isolates, and pandemic H1N1 has H5N1 polymorphisms, indicating exchanges via recombination have happened previously.

However- co-infection and co-transmission would significantly increase the frequency and efficiency of recombination, which would be serious cause for concerns.

Confirmation that these three patients have co-infections of H5N1 and H1N1 (or swine and seasonal H1N1) would be useful

-----------------------------------------

Sollte der Virus sich verbreiten muß ein NEUER Impfstoff dafür entwickelt werden, dann sind in der Zwischzeit Relanza oder Tamiflu die letzte Bastion die Krankeit zu behandeln !

Aktientechnisch gilt dann eher der Blick auf die antiviralen Grippemittel,
bzw. den Aktien Biota (Relenza + Laninamivir), Glaxo , Roche, Gilead (Tamiflu), Biocryst (Peramivir)

gruß
massel

[Massel]

News: Eine reine Relenza-Order für die Botschaftsangehörigen, Tamiflu ist in Canada auf dem Abstellgleis gelandet !

http://www.thestar.com/newsfeatures/swineflu/article/694722

Die Nachricht ist doch eigentlich der Knüller, denn damit wird die ernorme Gefahr der Tamiflu-resistenz offiziell durch eine Regierung bestätigt und die Änderung des prozentuallen Medikamtenmixes angekündigt.

Tamiflu ist auf dem Abstellgleis gelandet !

----------------------------------------------------------------

Sep 12, 2009 04:30 AM
Joanna Smith
Ottawa Bureau

OTTAWA–Canada is strengthening emergency stockpiles of antiviral drugs at its overseas missions so embassy and consular officials can get the same treatments for the swine flu pandemic as fellow citizens back home.

The federal government is buying 1,750 doses of the inhalable antiviral drug zanamivir (brand name Relenza) from GlaxoSmithKline Inc. for the foreign affairs department, according to a public procurement notice.

The contract gives the government the option to buy another 245,000 doses in the next two years for other departments.

Government contracts generally give a variety of vendors a chance to compete, but since this contract asks specifically for Relenza – which only GlaxoSmithKline can provide – firms that make other antiviral drugs are left out on this one.
That includes Roche Canada and its oseltamivir (brand name Tamiflu).

Rodney Moore, a spokesman for the Department of Foreign Affairs, said there have been stockpiles abroad since 2005 but, until now, only of Tamiflu.

Those drugs are expiring next February and as the government refreshes the supply it is also diversifying it to resemble the mix found in emergency stockpiles across Canada, which contain Tamiflu, Relenza and an older and inexpensive flu drug called amantadine.

"The choice of antiviral is based on the medical professional's analysis of each person's individual need and no particular antiviral is `favoured' over another," said Moore.

Moore said the Tamiflu and amantadine were ordered earlier this year.

Canada began adjusting its stockpiles this spring in response to concerns the H1N1 influenza virus was developing resistance to Tamiflu.

Chief Public Health Officer Dr. David Butler-Jones said most stockpiles around the world contain Tamiflu because it's a pill, which makes it easier to administer and store than Relenza, which is inhaled.
---------------------------------------------------------------
gruß
massel

[Massel]

Jetzt wir es interessant !

Biota vollzieht gerade einen Ausbruch in Australien:

Momentan + 11% auf 2.48 AUD

Kommt jetzt bald das Übernahmeangebot ?

gruß
massel

[Massel]

2.52 AUD =
neues 5-Jahreshoch

jetzt können die 4 AUD in Angriff genommen werden
oder der ALL-TIMEHIGH von 9.16 AUD
(laut comdirect-Chart)

08:10:32 2,520 3342
08:10:32 2,520 16
08:10:32 2,520 6642
08:10:32 2,520 1158
08:10:32 2,520 10000
08:10:32 2,520 8842
08:10:32 2,520 8620
08:10:32 2,520 1380
08:10:32 2,520 8620
08:10:32 2,520 1645
08:10:32 2,520 8355
08:10:32 2,520 1000
08:10:32 2,520 1000
08:10:32 2,520 3000
08:10:32 2,520 1000
08:10:32 2,520 1000
07:59:43 2,500 685
07:59:42 2,510 1233
-----------------------------------------
gruß
massel

[Massel]

Ich resümiere mal:

Biota hat heute einen aussergewöhnlichen Anstieg hingelegt.

Und das

-ohne News
-bei hohem Volumen
-besser als der ASX

und dazu den

-Widerstand von 2.25 AUD ganz locker schon zur Eröffnung gebrochen !

Bemerkenswert: Biota ADR´S in USA + 18 % auf 6.50 US , bei rund 46.000 Volumen !(immerhin) ; während wir in Deutschland "Ringelpietz mit anfassen spielen" scheinen die Amis langsam auf den Geschmack zu kommen und ord. Preis für Biotashares zu bezahlen.....

Weitere positve Vorgaben aus den USA, könnten uns für morgen eine schöne Unterstützung für einen weiteren Kurszuwachs geben.
Ich bin WIRKLICH der Meinung, dass es ggf. morgen zu einer handfesten Überraschung kommen könnte. (positiv)
Deswegen habe ich heute auch KEIN STÜCK versilbert.

AUF EINEN GRÜNEN MITTWOCH !

gruß
massel

[Massel]

Heilig´s Blechle

SK 2.56 AUD

was für eine Wochenausklang in Australien...Oh, OH, da werden heute einige Ramas draufgehen ....

Hier die fulminaten Schlußtrades:

08:10:46 2,560 4128
08:10:46 2,560 2000
08:10:46 2,560 5000
08:10:46 2,560 10000
08:10:46 2,560 4000
08:10:46 2,560 8500
08:10:46 2,560 2000
08:10:46 2,560 94458
08:10:46 2,560 1920
08:10:46 2,560 1327
08:10:46 2,560 1700
08:10:46 2,560 9273
08:10:46 2,560 727
08:10:46 2,560 4273
08:10:46 2,560 2000
08:10:46 2,560 3727
08:10:46 2,560 1867
08:10:46 2,560 1610
08:10:46 2,560 90
08:10:46 2,560 26
08:10:46 2,560 7
08:10:46 2,560 3218
08:10:46 2,560 3000
08:10:46 2,560 2000
08:10:46 2,560 10000
08:10:46 2,560 5000
08:10:46 2,560 1496
08:10:46 2,560 13504
08:10:46 2,560 1000
08:10:46 2,560 22267
08:10:46 2,560 11146
08:10:46 2,560 2299
08:10:46 2,560 5284
08:10:46 2,560 10874
07:59:55 2,490 633
07:59:55 2,490 5026
----------------------------

Ich sag nur noch PROST !

gruß
massel

[Massel]

----------------------------------------------------------

Gestern war ein sehr interessanter Bericht in PRO7 bei Gallileo
Spezial zum Thema Viren.

Zur Schweinegrippe haben die Experten folgendes gesagt:

20% der Erkrankten in Südamerika mussten intensiv-medizinisch betreut werden ( z.B. künstliche Beatmung), wären ansonsten gestorben ! (! von wegen harmlose Grippe !)

Für Deutschland wird folgendes Szenario erwartet:

Bei MILDEM Verlauf; 12 Mio Infizierte bei 40.000 Toten !

Bei SCHWEREM Verlauf; 40 Mio Infizierte bei 160.000 bis 200.000 Toten. Der Höhepunkt wird für Dezember erwartet.

BIOTA heute +2,91% auf SK 2.83 AUD

----------------------------------------------------------

[Massel]

BIOTA HIV-PATENT

Hier ein Post aus Australien zu dem Thema:

Ok, it looks like Biota has received a new patent for a previous breakthrough... so first I've copied the patent announcement (posted on SS) and then the original announcement titled "Biota Announces HIV Breakthrough from its US Research Group"... what's the significance? General interest I guess...

Thanks to theadder (from SS) for finding and posting this.

"From the USPTO a granted patent

http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=…

United States Patent 7,598,230
Cook , et al.
October 6, 2009

Nucleotide mimics and their prodrugs

Abstract

The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

Inventors: Cook; Phillip D. (Fallbrook, CA), Wang; Guangyi (Carlsbad, CA), Bruice; Thomas W. (Carlsbad, CA), Boyle; Nicholas A. (Encinitas, CA), Leeds; Janet M. (Encinitas, CA), Brooks; Jennifer L. (Encinitas, CA), Prhavc; Marija (Encinitas, CA), Ariza; Maria Eugenia (San Marcos, CA), Fagan; Patrick C. (Escondido, CA), Jin; Yi (Carlsbad, CA), Rajwanshi; Vivek K. (Vista, CA), Tucker; Kathleen D. (Escondido, CA)

Assignee:Biota Scientific Management Pty Ltd (Notting Hill, Victoria, AU)
"

And here is the original announcement in full:

"blot
For lmmediafe Release
Biota Holdings Limited
ACN 0% 479 081
Level 4
61 6 St Kitda Road
Melbourne Vic 3004
Australia
Tel. + 61 3 9529 231 1
Fax. + 61 3 9529 2261
www.biota.corn.au
Biota Announces HIV Breakthrough from its U5 Research Group
30 April 2003
Biota Hoidings Limited (ASX:ETA) announced today that its US subsidiary, Eiota Inc, had made an
important breakthrough in its program to develop a new drug to combat HIVIAIDS. Dr Dan Cook,
the President and Chief Scientist of 8iota tnc, presented the findings at the International
Conference on Antiviral Research (ICAR) in Savannah, Georgia, on 28 April.
Biota Inc, based in Carlsbad, California, employs its proprietary N-MAX technology to create
‘nucleotide mimics’, novel versions of nucleoside drugs, with the potential for enhanced activity
and reduced toxicity. Nucleoside drugs are widely used to treat diseases such as HIV/AIDS,
hepatitis C infection, and cancer. AZT (zidovudine), a leading anti-HIV nucleoside drug with sales
of around $1.5 billion*, has been a primary target for the Biota Inc research. The latest
achievement involves the discovery and initial testing of an AZT nucieotide mimic.
”The AZT-mimic research has been a remarkable success,” said Biota Group CEO, Peter Mofloy.
”In less than a year, Dan Cooks scientific team has demonstrated proof-ofconcept for the
N-MAX technology and discovered a series of novel cornpounds that could lead to new treatments
for HIV/AIDS.” The lead compound series, referred to as B-108, are covered by the patent
applications recently filed by Biota Inc.
Dr Cook presented data on the B-108 compounds at the CAR meeting, which included the results
of studies conducted by an independent laboratory in the US, using drug resistant HIV strains in
human cell cultures. The studies showed that the new compounds were many times more
effective than AZT, while having less toxicity.
”AZT is a good drug and a tough benchmark,” said Dr Cook. “These results are very promising.”
The 8-108 results are expected to generate interest among the companies in the HIV field,
opening the way for initiation of partnering discussions over the next few months. Meanwhile, the
US research team will continue to opfimise the current series of compounds, with the plan to
secure a development partner before taking any of the new compounds into ciinical development.
Biota Inc already has one important partnership in place, with GlaxoSmithKline, which is focused
on hepatitis C drug discovery and which generated $2.7 million in revenues for the Company in
the first half of this year.
Biota Inc is 88% owned by Eiota Holdings Limited (approximately 84% on a fully-diluted basis).
Biota Inc was provided with $15 million in initial equity funding by Biota Holdings, which was used
to establish the N-MAX laboratory facilities and scientific team in Carfsbad, California. The facility
has been fully operational since mid-2002.
For further information contact:
Mr Peter Molloy
Chief Executive Officer
Biota Hoidings Limited
Tel: [phone]
www.biota.com.au
* Sales denoted in Australian dollars. Bawd on 2002 sales data for Combivifi (marketed by GSK), a combination product of AZT and another
nucleoside drug, 3TC."
------------------------------

gruß
massel

[Massel]

Story Created: Oct 7, 2009 at 7:51 PM EDT

Story Updated: Oct 7, 2009 at 10:39 PM EDT

ELKHART COUNTY — Patient numbers are skyrocketing at local hospitals following the death of a South Bend girl that may be connected to the H1N1 flu. Some hospitals now estimate the increase in emergency room patients at close to 500 percent over the last few days alone, and doctors believe many do have the H1N1 virus.
South Bend girl’s death sparks concern about H1N1
No major spike in absenteeism at South Bend-area schools
South Bend schools say they’re prepared for H1N1
In most cases, patients are showing mild, but clear symptoms of the flu.

Among them:

-Severe or persistent vomiting or diarrhea
-Restlessness at night
-Significant change in fever, particularly spiking above 100 degrees F

On Wednesday night, local doctors held a community forum to clear up confusion about the rapidly spreading virus.
"We're seeing a lot of questions coming from the community. And our departments are fielding a lot of concerns about trying to stop the spread of the disease," said Elkhart General Hospital Community Outreach Coordinator Patty Gremaux.

Among the top concerns: how to tell if flu-like symptoms actually are H1N1?

"Right now, the influenza that's circulating does appear to be almost all H1N1," said Elkhart County Health Department Health Officer Dr. Daniel Nafziger.

Nafziger also serves as an infectious disease practitioner at Goshen Hospital.

"That's really the presumption that doctors are operating under--that, when people have flu-like symptoms, they have H1N1," Nafziger said.

That news caught some, like Jim Doering, off guard.

"I'm came here because I'm curious about what do I need to do? I'm highly scared of this," Doering said, flanked by his wife Linda Tolley and son Thomas.

"I have asthma, and I'm worried about being more prone to the virus," Doering continued.

"I also have a newborn grandson that I'm concerned about coming into contact with it," said Tolley.

"And my son, Thomas," added Doering quickly, eliciting a smile from the Northside Middle School-er.

It's the reason, Doering says, that's he's come up with a plan.

"We're going to look out. Look out for Thomas, and look out for us all," he said.

The problem?

"[We know] really nothing [about H1N1]. Just that it's out there," Tolley said.

It was a story repeated by in the crowd of about 75 people who gathered for the forum at Jimtown High School Wednesday night. And it was no surprise to local doctors, who have seen a huge increase in potential cases over the last few days.

"I've been quoting between 400 and 500 percent increase," said Dr. David VanRyn, Emergency Services Medical Director at Elkhart General.
"I don't have hard numbers, but, it's off the charts," he continued.

But most of those patients aren't being admitted because their symptoms are only mild.

"Most of the patients are treated and go home. most of the patients don't fit into the CDC guidelines of patients that require anti-viral treatments. So, it becomes a symptomatic treatment--aggressive treatment of fever, lots of fluids, and bed rest. And, people are getting better fairly quickly," VanRyn said.

It's a lucky break, because, right now, local stocks of Tamiflu and Relenza are down, said Nafziger. Same story with H1N1 vaccine.

As of late Wednesday, not a single dose had arrived in Elkhart County, and the first 2,600 doses in St. Joseph County were quickly given to first responders like paramedics, doctors and EMTs.

But, both are expected to be re-stocked quickly.

"We're hoping to begin seeing shipments coming in on [Thursday]," said Nafziger.

When supplies do arrive, the U.S. Centers For Disease Control recommends everyone between the ages of 2 to 64 get the vaccine-- with the exception of those with specific allergies to eggs.

Once the doses are on hand, local health departments will schedule flu shot clinics. The shots are free, but your medical provider can charge an administrative fee. Medicaid and most insurance companies will cover that cost.

In the meantime, experts are urging the public not to over-react or under-react.

"It's kind of a balancing act," said Nafziger. "On one hand, this isn't the real severe influenza we thought might be coming as the next pandemic. On the other hand, it can cause death. So, it isn't something to be taken too lightly, either."
------------------------------------------------------

gruß
massel

[Massel]

hier die Shortzahlen von gestern:
http://www.asx.com.au/data/shortsell.txt

BTA BIOTA HOLDINGS LIMITED FPO 1,031,461 Volumen

davon 95,548 Stück short = 9.26%

wie schon vermutete, der Kurs wird gedrückt, über 9% der gestern
gehandelten Aktien waren Shortkäufe. Einer der höchsten Tageswerte die ich je bei Biota gesehen habe !

SK 2.95 AUD


07:10:25 2,950 3800
07:10:25 2,950 3410
07:10:25 2,950 7493
07:10:25 2,950 300
07:10:25 2,950 207
07:10:25 2,950 5086
06:59:49 2,940 2000 DAS IST DER ÜBELTÄTER !
06:58:54 2,960 1575
06:58:54 2,960 1500
06:58:54 2,960 800
06:58:54 2,960 356
06:58:53 2,950 349
06:58:13 2,940 50

-------------------------------------

Ich denke wir sehen noch VOR dem Sharholdermeeting am 12.11 ein Übernahmeangebot; ansonsten ergeben die Shortkäufe und Kursdeckellungen keinen Sinn.
Wer sonst hätte eine Intention mit fast 100.000 Aktien gestern short zugehen ??

Jeden Augenblick kann eine Meldung zu einer fetten Relenzaorder oder zu Lani kommen, es gibt keinen handfesten Grund bei Biota "ehrlich" auf fallende Kurse zusetzten.

Nur wenn man sich die Firma "billigst" greifen will machen diese Transaktionen Sinn, da spielen die Paar hundertausend AUD die man durch die Shorttransaktion verliert keine Rolle, wenn man sie mit dem günstigeren Einkaufspreis der gesamten Firma verrechnet, bzw. gegenrechnet....

gruß
massel

[Massel]

WHO Reporting 31 Strains of the H1N1 Virus Resistant to Tamiflu
Sunday October 11, 2009
The World Health Organization (WHO) is reporting 31 strains of the H1N1 virus which have mutated and are now resistant to the anti-viral drug Tamiflu (oseltamivir). Since the outbreak of the current H1N1 pandemic Tamiflu has been at the front line of defense. Tamiflu is an antiviral drug which is capable of preventing someone from catching H1N1, (if taken within the first 48 hours after an individual has been exposed), reducing the duration and severity of the illness, and decreasing the risk of passing H1N1 on to others. Many health care workers have been taking Tamiflu to prevent catching H1N1 themselves.

Fortunately all 31 strains show a similar mutation and are still susceptible to another antiviral drug called Relenza (zanamivir). As of October 4, 2009 the WHO has reported 4,500 deaths worldwide. They also state that many countries have stopped documenting individual cases because many are mild and require no medical intervention. To date they are estimating 350,000 cases of H1N1 worldwide but state that this number is significantly lower than the actual number of cases occurred.

-----------------------------------------------


ASX im Minus und Biota legt zu !Das ist ja mal ein Wochenstart !

12.10.09 07:10 Uhr

3,12 AUD

+5,76 % [+0,17]

----------------------------------------------------

gruß
massel

[Massel]

Erhöhe mein persönliches Kursziel von Biota auf 10 AUD also ca. 6,12 Euro. (nächsten 12 Monate)

Hintergrund:

1.) zunehmende Tamiflu-Resistenz. Weitere Medienaufmerksamkeit und vorallem dürften hierdurch die jeweiligen Regierungen dazu gezwungen werden Ihre Medikamentenvorratung zugunsten Relenza zu verändern.

2.) Bei steigenden Kurs wir die Aufnahme in den ASX200 immer wahrscheinlicher. Hierzu ist ca. eine Marktkapitalisierung von rund 750 Mio AUD erforderlich. Dann wären auch Fonds gezwungen in Biota zu investieren, die den ASX200 nachbilden.

3.) Aufrund der hohen Cashbestände Biotas, bedingt durch die steigenden Relenzaeinnahmen wird ein Übernahmeszenario durch einen Pharmakonzern immer wahrscheinlicher. Weil Biota zusätzlich noch
über eine interessante Pipeline verfügt und mit Laninamivir bald über eine neue Einkommesquelle verfügen dürfte, sehe ich keinen Grund dafür, warum Biota nicht das Alltimehigh aus 1999 mit 9,10 AUD knacken sollte.

Die Firma steht besser dar als jemals zuvor. Daher wäre auch ein Übernahmepreis, bei dem momentanen Stand der Dinge, von 10 AUD absolut gerechtfertigt.

gruß
massel

[Massel]

hab heute Post gehabt:
(schaut mal in eure Briefkästen)

Sehr geehrter Kontoinhaber.....

die oben genannte Gesellschaft Biota....
hat unter Berufung auf in Australien gültiges Gesellschaftsrecht von unserem hause die Offenlegung der Namen und Anschriften Ihre Aktionäre verlangt....
--------------------------------------

Normalerweise würde ich sagen, dass dies mit dem Sharholdermeeting zu tun hat, auf der anderen Seite, war hier vorher aber seitens Biota die Rede davon, dass die Aktionäre sich selber darum kümmern/melden müssen,wenn Sie von Ihrem Wahlrecht gebrauch machen wollen...

Von daher bin schon ein bißchen verwundert !

Oder flattert uns bald das Übernahmeangebot ins Haus ??

gruß
massel

[Massel]

16.10.2009 15:37
Roche schließt weitere Zukäufe im Mrd-USD-Bereich nicht aus
DJ Roche schließt weitere Zukäufe im Mrd-USD-Bereich nicht aus

FRANKFURT (Dow Jones)--Das Pharma- und Diagnostikunternehmen Roche schließt trotz der 46,8 Mrd USD schweren Übernahme des US-Biotechnologiekonzerns Genentech in diesem Jahr für die Zukunft Übernahmen im Mrd-USD-Bereich nicht aus. "Ich würde neben kleineren Zukäufen auch solche Ziele wie die Ventana-Akquisition nicht ausschließen, wenn es wirklich gut zu unserem Portfolio passt", sagte der CEO der Roche-Gruppe, Severin Schwan, am Rande einer Pressekonferenz in Frankfurt. Den US-Diagnostikspezialisten Ventana hatte Roche Anfang 2008 für 3,4 Mrd USD gekauft.

Trotz des steigenden Drucks im Gesundheitswesen zeigte sich Schwan zuversichtlich für die weitere Zukunft des schweizerische Konzerns. "Alles hängt davon ab, ob wir innovative Medikamente weiter bringen oder nicht", erklärte er. Roche habe zehn Produkte in der späten Phase der Entwicklung. "Wenn alle von den zehn Produkten durchkommen mit dem Profil, wie wir es erwarten, und die Studien alle positiv sind, dann brauchen Sie sich über die Gewinne von Roche keine Sorgen mehr zu machen", fügte er hinzu.

Die Innovation sei bei all diesen Produkten so stark, dass Roche dann auch angemessene Preise verlangen könne. "Wir sind zuversichtlich dass ein großer Teil dieser Produkte auf den Markt kommt", sagte der Manager. Damit sei er auch zuversichtlich, dass sich das Geschäft von Roche von der finanziellen Seite her positiv entwickeln werde, ergänzte Schwan.

Für das Arthritis-Mittel "Actemra" erwartet Schwan die Zulassung in den USA Anfang 2010. Im Juli hatte die FDA den erneuten Zulassungsantrag der Roche Holding AG für Actemra zur Behandlung der rheumatoiden Arthritis in den USA akzeptiert. Das Mittel, das in Europa unter dem Namen "RoActemra" gehandelt wird, ist in acht EU-Märkten, darunter Deutschland sowie unter anderem in Indien und Brasilien bereits auf dem Markt.

------------------------------------------------------------------


http://www.spiegel.de/wissenschaft/medizin/0,1518,655453,00.…

Anti-Grippe-Mittel
Ärzte befürchten massive Tamiflu-NebenwirkungenVon Gerald Traufetter und Christoph Seidler

DPA
Medikament Tamiflu: "Wir müssen schnell wissen, was es mit den Nebenwirkungen auf sich hat."
Das Medikament Tamiflu soll im Falle einer aggressiven Schweinegrippe-Pandemie massenhaft zum Einsatz kommen. Doch aus Japan gibt es zahlreiche Berichte über angebliche Nebenwirkungen, vor allem bei jungen Patienten. Der Hersteller sagt, das habe nichts mit dem Medikament zu tun.

Für den Schweizer Pharmakonzern Roche ist das Anti-Grippe-Mittel Tamiflu der Verkaufsschlager schlechthin. Am Donnerstag verkündete das Unternehmen neun Prozent mehr Umsatz in den ersten drei Quartalen - vor allem dank der immer noch steigenden Verkaufszahlen von Tamiflu, das seit Jahresanfang 1,3 Milliarden Euro in die Kassen von Roche gespült hat.

Doch nun warnen Pharma-Experten im renommierten Fachblatt "The Lancet" vor möglichen gefährlichen Nebenwirkungen des Mittels und fordern, entsprechende Berichte schnell zu überprüfen. Das Medikament ist millionenfach von den Behörden eingelagert worden, um gegen die Schweinegrippe-Pandemie gewappnet zu sein. "Wir müssen schnell wissen, was es mit den Nebenwirkungen auf sich hat", sagt der Hauptautor der Studie, der Influenza-Experte Tom Jefferson von der Cochrane Collaboration, zu SPIEGEL ONLINE. Er hatte zuvor bereits die Vermutung geäußert, dass Grippemittel wie Tamiflu oder Relenza die Sterblichkeit bei Grippe nicht nachweislich senken. Die Dauer der Grippe werde im Durchschnitt um einen Tag verkürzt, sagte Jefferson im Sommer dem SPIEGEL.

"Geschockt, wie wenig die Behörden über Nebenwirkungen wissen"

In Japan, wo Tamiflu schon seit Jahren verschrieben und auch massenhaft eingenommen wird, vermuten Mediziner bei drei Prozent aller Heranwachsenden eine Verhaltensveränderung nach Einnahme von Tamiflu. Das Spektrum reiche von Halluzinationen bis hin zu Unfällen, die sich aufgrund der Persönlichkeitsveränderungen ereignet hätten. Jefferson hat zudem auf dem Rechtsweg bislang geheime Daten der US-Ernährungs- und Arzneimittelbehörde FDA besorgt, um nach möglichen weiteren Hinweisen auf psychiatrische Effekte zu fahnden. "Ich war erschrocken, wie wenig die Behörden eigentlich über die Nebenwirkungen von Tamiflu wissen", sagt Jefferson.

Insgesamt ist in "The Lancet" von 2275 Berichten über unerwünschte Nebenwirkungen die Rede. Bei Jugendlichen seien meist auffälliges Verhalten, Krämpfe, Delirium und Halluzinationen beobachtet worden. Ältere Personen hätten hingegen unter Erbrechen und Übelkeit gelitten. "Wir können nicht eindeutig sagen, ob Tamiflu diese psychiatrischen Effekte verursacht oder ob es mit der Grippe zusammenhängt", so Jefferson.

In jedem Falle sei es aber "äußerst merkwürdig", dass die Japaner auf drei Prozent solcher Nebenwirkungen bei Jugendlichen stießen, der Hersteller Roche in seinen Studien aber "keinen einzigen solchen Fall berichtet", so Jefferson. "Was wir jetzt brauchen, sind unabhängige Studien." Insbesondere, weil die Weltgesundheitsorganisation (WHO) und die amerikanische FDA das Präparat für unbedenklich zum massenhaften Gebrauch an Kindern und Jugendlichen erklärt hätten. "Die Zeit drängt", so Jefferson.

Roche sieht keine neue Faktenlage

Nach Ansicht der Herstellerfirma Roche ergibt sich durch den Bericht indes keine neue Faktenlage. Das teilte ein Firmensprecher auf Anfrage von SPIEGEL ONLINE mit. Seit 1999 hätten sich Ärzte weltweit in knapp 60 Millionen Fällen entschieden, schwer erkrankte Influenza-Patienten mit Tamiflu zu behandeln. "Bei dieser Vielzahl von Behandlungen konnte bislang kein kausaler Zusammenhang zwischen der Einnahme des Wirkstoffs Oseltamivir und auffälligen psychiatrischen Verhaltensstörungen festgestellt werden", erklärte der Sprecher.

Patienten mit Influenza könnten durch hohes Fieber "ein abnormales Verhalten entwickeln", zum Beispiel im Form von Fieberträumen, Halluzinationen und Delirium. "Dies kann unabhängig davon vorkommen, ob die Patienten mit einer antiviralen Therapie behandelt werden oder nicht." Die aktuellen Empfehlungen der Weltgesundheitsorganisation sowie der Seuchenbekämpfungsbehörden in den USA und Europa zur Therapie der Schweinegrippe würden diese Einschätzung unterstreichen.

-------------------------------------------
gruß
massel

[Massel]

Aktuelle Nachricht:

By Andrea Gerlin

Oct. 22 (Bloomberg) -- The number of new swine flu cases in England almost doubled in the past week to 53,000 from 27,000 the previous week, the country’s top doctor said today.

The H1N1 virus that causes swine flu has killed 122 people in the U.K., up 16 in the last week, since April, England’s Chief Medical Officer Liam Donaldson said at a press conference. The number of people hospitalized with the illness rose to 506, including 99 in intensive care, the highest level since the pandemic began, Donaldson said.

“Over the last week we’ve seen a faster rate of increase than we’ve seen in the last few weeks,” Donaldson said.

The U.K. began its vaccination program yesterday by immunizing workers at University College London Hospital, Donaldson said. Medical personnel, pregnant women, people who have regular contact with those who have weakened immune systems, and people with underlying health conditions who usually get priority for seasonal flu shots are the first to get inoculated against swine flu.

The Department of Health may announce additional priority groups next month, Donaldson said. Businesses have asked the agency whether they can obtain vaccine to administer to their workers, he said.

“We’re not in a position yet to extend the vaccine program” to healthy people, he said.

The health department’s updated estimates suggest that 5 percent of the workforce may be absent from their jobs and 1.5 million people a week may be ill during the peak of the pandemic this winter. As many as 35,000 people could be hospitalized, 15 percent of them in intensive-care beds, placing pressure on the National Health Service into early 2010.

“What we’re starting to worry about is partly the peak that we might see this flu season, but we’re also starting to worry about the sustained pressure over the winter that the NHS might face,” Donaldson said. “The NHS has never before had a run from the middle of July right through to March or April with intensive infectious disease activity like this, not in modern times anyway.”

To contact the reporter responsible for this story: Andrea Gerlin at [e-mail]

--------------------------------------

- desweiteren ist neuer Tamiflu-Resistenzfall in Hongkong gemeldet worden.

Gruß
massel

[Massel]

Hong Kong (HKSAR) - The Department of Health's Public Health Laboratory Services Branch (PHLSB) today (October 22) detected a strain of human swine influenza (HSI) virus which was resistant to oseltamivir (Tamiflu). A department spokesman said the virus was identified during PHLSB's sensitivity test of HSI virus to oseltamivir and zanamivir. "This is the fourth time Tamiflu resistance in HSI virus is found in Hong Kong and is the third local case.

"Tests showed that this strain is sensitive to zanamivir (Relenza)," he said. The virus was isolated from the specimen taken from a 16-year-old girl who developed flu-like symptoms on September 14 and attended a Designated Flu Clinic on September 16. Her respiratory specimen tested positive for HSI.

Further test results today showed that the virus was resistant to Tamiflu. She had no history of taking Tamiflu before the specimen was taken. The girl has already recovered.

Investigations revealed that her five family members did not have respiratory symptoms. There was no recent influenza-like-illness outbreak in the school she attended. The spokesman said that PHLSB conducted routine sensitivity tests on specimens taken from confirmed HSI patients.

So far more than 5,000 HSI samples had been tested for anti-viral sensitivity in Hong Kong. The case will be reported to the World Health Organisation (WHO), the spokesman said. He reiterated that Hong Kong had an intensive surveillance system of antiviral resistant influenza viruses.

"We will closely liaise with the WHO and overseas health authorities to monitor the global development of antiviral-resistant HSI virus," he said.

----------------------------------------------

bedenklich, dass das Mädchen vorher kein Tamiflu bekommen hatte, denn damit steht im Umkehrschluß eindeutig fest, dass es sich hier um eine echte, von einer Fremdperson übertragenene, Tamiflu resistente Virusvariante handelt.

Tamiflu scheint auf Zeit ausgedient zu haben, bzw wirkungsklos zu werden..

Gruß
massel

[Massel]

Pandemic (H1N1) 2009 - update 71 (WHO vom 23.10.2009)
Weekly update

As of 17 October 2009, worldwide there have been more than 414,000 laboratory confirmed cases of pandemic influenza H1N1 2009 and nearly 5000 deaths reported to WHO.

As many countries have stopped counting individual cases, particularly of milder illness, the case count is significantly lower than the actually number of cases that have occurred. WHO is actively monitoring the progress of the pandemic through frequent consultations with the WHO Regional Offices and member states and through monitoring of multiple sources of data.

New Activity:

Mongolia, Rwanda, and Sao Tome and Principe have reported pandemic influenza cases for the first time this week.

Iceland, Sudan, and Trinidad and Tobago reported their first fatal cases.

Situation update:

In general, influenza activity in the northern hemisphere is much the same as in the last week, though respiratory disease activity continues to spread and increase in intensity. In North America, the U.S.A. is still reporting nationwide rates of Influenza-Like Illness (ILI) well above baseline rates with high rates of pandemic H1N1 2009 virus detections in clinical laboratory specimens (29% of all specimens tested are positive for influenza A and all of those subtyped are pandemic H1N1 2009 virus. Canada reports increases in ILI rates for the fourth straight week but the highest level of activity is in the western province of British Columbia. Mexico still reports active transmission in some areas of the country. Although influenza activity is low in most countries in Europe, in Belgium, Israel, the Netherlands, Norway, and parts of the United Kingdom consultation ILI/ARI rates are above baseline levels. Similarly the number of influenza virus detections relatively high, which may indicate the early start of an influenza season. Rates of respiratory illness in Eastern Europe and Northern Asia are increasing but are not yet at levels normally seen in an influenza season (baseline levels are not defined in many countries of the area). Of note, the proportion of cases in Asia that are related to seasonal influenza A(H3N2) continue to decline globally as the proportion related to pandemic H1N1 2009 virus increases. Currently, only East Asia is reporting any significant numbers of influenza A(H3N2) isolates.

In tropical areas of the world, rates of illness are generally declining, with a few exceptions. Cuba, Colombia, and El Salvador are reporting increases in the tropical region of the Americas. In tropical Asia, of the countries that are reporting this week, all report decreases in respiratory disease activity.

The temperate region of the southern hemisphere has no significant pandemic related activity in the past week.
Weekly update (Virological surveillance data)

*Countries in temperate regions are defined as those north of the Tropic of Cancer or south of the Tropic of Capricorn, while countries in tropical regions are defined as those between these two latitudes.
Qualitative indicators (Week 29 to Week 40: 13 July - 4 October 2009)

The qualitative indicators monitor: the global geographic spread of influenza, trends in acute respiratory diseases, the intensity of respiratory disease activity, and the impact of the pandemic on health-care services.
Human infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance
A description of WHO pandemic monitoring and surveillance objectives and methods can be found in the updated interim WHO guidance for the surveillance of human infection with pandemic (H1N1) virus.

The maps below display information on the qualitative indicators reported. Information is available for approximately 60 countries each week. Implementation of this monitoring system is ongoing and completeness of reporting is expected to increase over time.
List of definitions of qualitative indicators
Geographic spread of influenza activity
Map timeline
Trend of respiratory diseases activity compared to the previous week
Map timeline
Intensity of acute respiratory diseases in the population
Map timeline
Impact on health care services
Map timeline
Laboratory-confirmed cases of pandemic (H1N1) 2009 as officially reported to WHO by States Parties to the IHR (2005) as of 11 October 2009
Map of affected countries and deaths

The countries and overseas territories/communities that have newly reported their first pandemic (H1N1) 2009 confirmed cases since the last web update (No.70): Mongolia, Rwanda and Sao Tome and Principe.

The countries and overseas territories/communities that have newly reported their first deaths among pandemic (H1N1) 2009 confirmed cases since the last web update (No 70): Iceland, Sudan and Trinidad and Tobago.

Region


Cumulative total

as of 18 October 2009




Cases*


Deaths

WHO Regional Office for Africa (AFRO)


13297


75

WHO Regional Office for the Americas (AMRO)


160129


3539

WHO Regional Office for the Eastern Mediterranean (EMRO)


14739


96

WHO Regional Office for Europe (EURO)


Over 63000


At least 261

WHO Regional Office for South-East Asia (SEARO)


41513


573

WHO Regional Office for the Western Pacific (WPRO)


122267


455









Total


Over 414945


At least 4999

*Given that countries are no longer required to test and report individual cases, the number of cases reported actually understates the real number of cases.

[Massel]

NEWS: Markteinführung von Laninamivir: Es scheint bals soweit zu sein....

The Private Healthcare Sector In Portugal Is Worth Approximately US$994mn- US$1.14bn Annually
New report provides detailed analysis of the Healthcare and Medical market
Published on October 23, 2009

by Press Office

(Companiesandmarkets.com and OfficialWire)

LONDON, ENGLAND

Portugal Pharmaceuticals and Healthcare Report Q4 2009

BMI calculates that pharmaceutical sales in Portugal reached EUR3.61bn (US$5.31bn) in 2008. We calculate that the sales of prescription and over-the-counter (OTC) medicines will reach a value of EUR0.302bn by 2013, equating to a constant annual growth rate (CAGR) of 2.79% in local currency terms. We note that as a result of the weakening euro, drug market expenditure in US dollar terms will experience a decline 2009, 2010, 2011 and 2012, before reaching a value of US$5.11bn by 2013, equating to a CAGR of -0.77%.

In BMI’s Q409 Business Environment Ratings table for Western Europe, Portugal scores 59.7, down from its Q309 score of 62.6. In regional terms, Portugal is rated 8th of the 9 countries in the Western Europe matrix, above Italy and below Belgium. In global terms, Portugal is positioned in 15th place (down one place compared to the previous quarter), above the Czech Republic and the United Arab Emirates (UAE) and below Belgium and the Netherlands, out of the 71 markets surveyed by BMI. The government plays a significant role in the healthcare. Public sector expenditure accounted for 70.5% of spending in 2008. However, an increase in the uptake of private insurance will result in this number falling to 69% over the next five years.

In July 2009, new data showed that approximately a third of the population (3mn out of 10.7mn) are turning to the private sector for treatment, a figure that has tripled over the past 30 years. The private healthcare sector in Portugal is worth approximately US$994mn- US$1.14bn annually and in 2008, the Mello Group’s private healthcare scheme earned revenues of US$397mn, Banco Esperito Santo’s private healthcare plan earned revenues of US$119mn and stateowned Caixa Geral de Depositos’ healthcare scheme earned US$89mn. In August 2009, Portugal’s National Health Plan said that the consumption of sedatives and antidepressants in Portugal is on the rise.

Consumption of anxiolytics, soporifics, sedatives and antidepressants increased by 32% between 2002 and 2008. In Portugal in 2002, 115.6 doses of sedatives and antidepressants were consumed per 1,000 inhabitants per day, and by 2008 this figure had increased to 152.1 doses per 1,000 inhabitants per day. Portugal is therefore way above the European average for consumption of this type of medicine, which stands at 41.3 doses per 1,000 people per day. The National Health Plan aims to reduce the consumption of sedative and antidepressant medicines to 92.5 doses per 1,000 inhabitants per day by 2010. In September 2009, Hovione announced its plans to move to large-scale manufacture of its TwinCaps inhaler, following its use in Phase III trials of Daiichi Sankyo/Biota’s long-acting neuraminidase inhibitor, laninamivir (CS-8958). Daiichi Sankyo and Biota have a worldwide licence to use TwinCaps for the treatment and prevention of influenza infections and it is available for licensing in other indications, according to Hovione.


Portugal Pharmaceuticals and Healthcare Report Q4 2009: http://www.companiesandmarkets.com/r.ashx?id=4RI64M9S6162262

--------------------------------------

Das sieht nach baldiger Markteinführung von LANINAMIVIR AUS !

Gruß
massel

[Massel]

Der Aktionär empfiehlt Biota mit Kursziel 2.80 € in seiner neuesten Ausgabe..
---------------------------------------------------------------

http://www.who.int/csr/don/2009_11_03/en/index.html

Pandemic (H1N1) 2009, Ukraine - update 1

3 November 2009 -- According to the Ministry of Health of Ukraine, the country has now recorded more than 250 000 cases of influenza-like illness, with 235 patients requiring intensive care. As of 2 November, 70 deaths from acute respiratory illness have been reported.

Regions in western Ukraine continue to show the highest rates of acute respiratory illness/influenza-like illness. The level of activity in the Kyiv area is also increasing rapidly.

Laboratory testing in Ukraine has confirmed pandemic H1N1 influenza virus in samples taken from patients in two of the most affected regions. As the pandemic virus has rapidly become the dominant influenza strain worldwide, it can be assumed that most cases of influenza in Ukraine are caused by the H1N1 virus.

As elsewhere, WHO strongly recommends early treatment with the antiviral drugs, oseltamivir or zanamivir, for patients who meet treatment criteria, even in the absence of a positive laboratory test confirming H1N1 infection.

At the request of the government, a multi-disciplinary team of nine experts has been deployed by WHO and arrived in Kyiv yesterday evening. Discussions with the Minister of Health were held this morning to brief the team.

Team members will now begin field investigations to characterize the clinical and epidemiological features of the outbreak. Work will initially begin in Lviv region, where reported numbers of cases showing severe manifestations of acute respiratory illness have been especially high. Two virologists on the team have started working at the National Influenza Centre and the laboratories of the Central Sanitary and Epidemiological Station in Kyiv to provide diagnostic support.

Samples sent by the Ministry of Health were received today by the WHO Collaborating Centre for Reference and Research on Influenza, Mill Hill in London, UK. The laboratory will conduct confirmatory tests and further characterize the virus.

Many questions remain to be answered. The outbreak in Ukraine may be indicative of how the virus can behave in the northern hemisphere during the winter season, particularly in health care settings typically found in Eastern Europe.

Given the potential significance of this outbreak as an early warning signal, WHO commends the government of Ukraine for its transparent reporting and open sharing of samples.

WHO continues to recommend no closing of borders and no restrictions on international travel, including to Ukraine. Experience shows that such measures will not stop further spread of the virus.

-------------------------

gruß
massel

[Massel]

BREAKING NEWS

Top-Aktuelle News (mit Zeitvorsprung zu Australien morgen):

http://www.chinadaily.com.cn/bizchina/2009-11/18/content_899…

Anti-flu drug on its way to China
By Ma Zhenhuan (chinadaily.com.cn)
Updated: 2009-11-18 17:25

Pharmaceutical manufacturer GlaxoSmithKline (GSK), wants to move some production of its anti-flu drug Relenza to China.

"I hope that we will be able to bring some Relenza manufacturing here to China, so that we can be in a position that more of our products are for the Chinese population," Andrew Witty, GSK's CEO, said today in Shanghai.

The drug, which won State Food and Drug Administration (SFDA) approval in September for domestic sales, is one of the two main drugs used against the influenza virus, together with Roche's Tamiflu.

Witty said his company is the only one that produces both vaccines and treatment to fight the H1N1 influenza.

According to him, GSK has developed three main products around the swine flu: its vaccine, anti-viral face masks, and anti-viral medicines such as Relenza.

Around 450 million to 500 million doses of anti-swine-flu vaccine will be shipped from now to next year, including somewhere over 60 million packs of Relenza, Witty said.

---------------------------------------------------------------------------------

60 Mio. Dosen war die alte Jahresproduktion von Glaxo;
bevor sie vor kurzem erst auf 90 Mio hochgeschraubt wurde und letztendlich in 190 Mio. ihr Hoch erreichen wird.

Mit 60 Mio. Dosen geht also die komplette ehemalige Jahreproduktionskapazität Relenza´s von Glaxo alleine nach China
und zwar von heute innerhalb eines Jahres !!

Es muß ernsthaft die Frage gestellt werden ob Glaxo mit 190 Mio Dosen jährlich überhaupt hinkommt, wenn 60 Mio. alleine nach China gehen !

gruß
massel